Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1
|Study Design:||Endpoint Classification: Efficacy Study
Primary Purpose: Prevention
|Official Title:||A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand|
|Study Start Date:||March 1999|
|Estimated Study Completion Date:||August 2000|
Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior effects associated with study participation are assessed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006327
|Klongsan / Bangkok, Thailand|
|Principal Investigator:||Kachit Choopanya|